

Parkinson's Disease Drug Market Driven by Cell Therapy & Gene-Based Treatments | DataM Intelligence

The Parkinson's therapeutics market will grow from USD\$5.92Bn in 2024 to USD\$12.83Bn by 2033 at 8.1% CAGR, driven by novel therapies and global investment.

TEXAS, TX, UNITED STATES, July 30, 2025 /EINPresswire.com/ -- [Parkinson's disease therapeutics](#) encompass drugs, device-based delivery systems, and emerging gene- or cell-based interventions aimed at managing motor and non-motor symptoms.

Based on DataM Intelligence analysis, the market reached approximately USD 5.92 billion in 2024 and is projected to soar to USD 12.83 billion by 2033, at a compound annual growth rate of around 8.1%. Growth drivers include an aging global population, rising disease prevalence, and intensified R&D into disease-modifying treatments.

Download exclusive insights with our detailed sample report (Corporate Email ID gets priority access): <https://www.datamintelligence.com/download-sample/parkinsons-disease-therapeutics-market>


Parkinson's Disease Therapeutics Market Segments

By Drug Class:

Levodopa/carbidopa remains the dominant segment, accounting for over 50% of global revenue due to its long-standing efficacy and affordability. Meanwhile, dopamine agonists are the fastest-growing class, recently bolstered by new approvals such as apomorphine infusion devices and D1/D5 selective agonists like tavapadon.

By Route of Administration:

Oral formulations continue to dominate (approximately 63–75% share) due to convenience and reimbursement coverage. However, subcutaneous and infusion therapies, offering continuous



symptom control are expanding most rapidly with recent regulatory approvals.

Key Players & Pipeline Highlights in Parkinson's Disease Therapeutics Market

Leading companies include AbbVie, Eisai, Novartis, Kyowa Kirin, Teva, Boehringer Ingelheim, Roche, and Acadia Pharmaceuticals.

Notable pipeline assets include:

- Tavapadon (Cerevel Therapeutics): A D1/D5 receptor partial agonist now completing Phase III trials for early-stage PD.
- Prasinezumab (Roche/Prothena): Anti- α synuclein monoclonal antibody entering Phase III for early PD, marking a shift toward disease-modifying treatments.
- NEULARK (Neuron23 Inc.): A brain-penetrant LRRK2 inhibitor currently in Phase II studies using digital biomarkers to improve precision in early-stage PD treatment.

Regional Market Dynamics

- North America dominates with roughly 40% of global market share in 2024, underpinned by high PD prevalence, strong diagnostics, and early adoption of advanced therapies including infusion systems and DBS.
- Europe contributes around 30%, supported by solid reimbursement frameworks, disease awareness, and robust access to both conventional and novel therapies (e.g., new delivery platforms).
- Asia Pacific (~18%) is the fastest-growing region, driven by aging demographics in China, India, and Japan, increasing diagnosis rates, and expanded telehealth access in rural areas.
- Middle East & Africa (~7%) are emerging markets, led by economic growth and improving access in GCC countries like Saudi Arabia and the UAE.
- Latin America (~5%) shows modest growth, primarily in Brazil and Argentina, with increased access to generics and rising public chronic disease strategies.

Looking for in-depth insights? Grab the full report: <https://www.datamintelligence.com/buy-now-page?report=parkinsons-disease-therapeutics-market>

Investments & Strategic Moves in Parkinson's Disease Therapeutics Market

United States

- July 2024: Merz Therapeutics completed its acquisition of INBRIJA (levodopa inhalation) and FAMPYRA (dalfampridine) from Acorda, expanding its neurology portfolio.
- September 2024: AbbVie reported positive Phase III data from the TEMPO-1 trial of tavapadon as a monotherapy for early PD, highlighting its potential as a once-daily oral agent.

Japan

- 2025 (ongoing): Japan's METI and health sectors continue to subsidize drug discovery ventures in dementia and neurodegeneration, including Parkinson's candidates like Sumitomo Pharma's DSP 1083 cellular medicine initiative.

Europe & Other Regions

- July 2024: The Michael J. Fox Foundation granted £4.7 million to Scottish-based Lario Therapeutics, supporting development of a calcium channel inhibitor targeting early PD progression.
- In Europe, Roche's advancement of prasinezumab into Phase III trials also catalyzes broader investment and academic engagement across Western neuroscience centers.

Parkinson's Disease Therapeutics Market Trends & Emerging Opportunities

- Disease-Modifying Therapies: A shift toward α -synuclein-targeting antibodies and LRRK2 inhibitors promises to address progression, not just symptoms.
- Digital Biomarkers & Personalization: Tools like gait/speech analysis and AI-driven phenotyping are enhancing precision medicine approaches.
- New Delivery Formats: Continuous infusion pumps and inhaled levodopa offer better fluctuation control, supporting patient adherence.
- Combination Therapies: Multi-modal regimens integrating neuroprotective agents, lifestyle interventions, and device support signify holistic treatment models.

Parkinson's Disease Therapeutics Market Challenges & Future Outlook

Challenges:

- High R&D Costs: Clinical development for novel biologics, gene therapies, or delivery devices remains expensive and lengthy.
- Regulatory Complexity: Approvals for infusions and disease-modifying therapies vary globally and require robust biomarker validation.
- Alternative Treatment Growth: Deep brain stimulation, physical therapy, and lifestyle interventions are reducing sole reliance on pharmaceuticals.

Future Outlook:

With its estimated near doubling by 2033, the Parkinson's therapeutics market is entering a transformative era. Stakeholders aligning innovation in non-dopaminergic drugs, digital biomarkers, advanced delivery systems, and global partnerships particularly across North America, Europe, and Asia-Pacific stand to lead this highly competitive and life-changing field.

Unlock 360° Market Intelligence with 2 Days FREE Trial Access of DataM Subscription Now!:

<https://www.datamintelligence.com/reports-subscription>

- Technology Roadmap Analysis
- Sustainability Impact Analysis
- KOL / Stakeholder Insights
- Pipeline Analysis For Drugs Discovery
- Positioning, Pricing & Market Access Snapshots
- Market Volatility & Emerging Risks Analysis
- Competitive Landscape

Have a look at our Subscription Dashboard: <https://www.youtube.com/watch?v=x5oEiqEqTWg>

Related Reports:

[Alzheimer Drugs Market Size](#)

[Migraine Drugs Market Growth](#)

Sai Kumar

DataM Intelligence 4market Research LLP

+1 877-441-4866

sai.k@datamintelligence.com

Visit us on social media:

[LinkedIn](#)

[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/835386006>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.